美国休斯敦德州大学MD安德森癌症中心的研究人员已经发明了一种“两步”卵巢癌筛查法,通过测定血液中CA125(一种肿瘤标志物)蛋白的变化来筛查癌症。研究人员称,如果这种新的筛查办法通过了临床试验,仅在美国,它就可以拯救成千上万的女性。研究进行了11年,纳入了4051名绝经后的女性,从试验一开始,她们每年接受CA125 Researchers at the MD Anderson Cancer Center at the University of Texas MD in Houston have invented a “two-step” ovarian cancer screening test to screen for cancers by measuring changes in CA125, a tumor marker protein in the blood. Researchers say that if this new screening test passes clinical trials, it could save tens of thousands of women in the United States alone. The study was conducted for eleven years and included 4,051 post-menopausal women who, starting from the start of the trial, received an annual CA125